The diabetes medication semaglutide has recently become a trendy weight loss treatment. But like every drug, there are ...

As of February 2025, the semaglutide injection (Ozempic, Wegovy) shortage was resolved. As a result, compounded semaglutide ...

Learn more about what to expect if you’ve been prescribed this weight loss medication to help treat this chronic liver condition.

The GLP-1 (Glucagon-like Peptide-1) market presents a significant opportunity, particularly given the upcoming patent expiry of semaglutide across key markets. GLP drugs, often called miracle drugs, ...

Semaglutide, the drug behind the blockbuster weight-loss jabs Ozempic and Wegovy, does not slow cognitive decline in people with early-stage Alzheimer's, according to two large new studies. The ...

Weight-loss drug semaglutide, also used to treat type-2 diabetes, will face its next big turning point in early 2026, when patents held by Novo Nordisk expire in India. The Danish company sells the ...

The U.S. has revealed price reductions for the second round of prescription drugs negotiated by the Centers for Medicare & Medicaid Services (CMS) through the Inflation Reduction Act (IRA). Headlining ...

Novo Nordisk's semaglutide fails in Alzheimer's trials Trials aimed for 20% slowing of cognitive decline in Alzheimer's More details to be released at December 3 meeting COPENHAGEN, Nov 24 (Reuters) - ...

Novo Nordisk said on Monday an older oral version of its semaglutide drug failed to meet its main goal in late-stage trials testing whether the medicine can slow cognitive decline in Alzheimer’s ...

Novo Nordisk has come up short in two phase 3 trials of semaglutide as a treatment for Alzheimer’s disease (AD). But perhaps the larger story associated with the unsurprising result is the market ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression of Alzheimer’s disease in closely watched trials, drugmaker Novo Nordisk ...